This application is subject to PEP 1308.	KISHI ET AL.  Art Unit  1623  correspondence address plication. If not included a will be mailed in due course. THIS be withdrawal from issue at the initiative
ner  the cover sheet with the communication appropriate communication This application is subject to EP 1308.	1623  orrespondence address plication. If not included will be mailed in due course. THIS
the cover sheet with the community that the community appropriate communication This application is subject to PEP 1308.	orrespondence address plication. If not included will be mailed in due course. THIS
MAINS) CLOSED in this appropriate communication This application is subject to PEP 1308.	plication. If not included will be mailed in due course. <b>THIS</b>
J.S.C. § 119(a)-(d) or (f).	
eceived in Application No have been received in this communication to file a reply this application.  Set the attached EXAMINER n(s) why the oath or declara- comitted.	national stage application from the complying with the requirements  'S AMENDMENT or NOTICE OF stion is deficient.
dment / Comment or in the C	Office action of
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.	
6. ☐ Interview Summary Paper No./Mail Da 7. ☐ Examiner's Amenda	te
6 S	communication to file a reply this application.  Interview Summary Paper No./Mail Da 7. ☐ Examiner's Statemed.

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Part of Paper No./Mail Date 20041220

Application/Control Number: 10/054,482

Art Unit: 1623

Applicant's amendments and remarks filed on 09/20/04 are acknowledged. Claims 1,7 and 12 have been amended. Claims 8 and 11 have been cancelled.

The rejections of claims 1-7,9,10 and 12 under 35 U.S.C., 112, second paragraph have been overcome through applicants' amendment to the claims.

The examiner withdraws the rejection of claims 1-7,9,10 and 12 under obviousness-type double patenting as being unpatentable over US 6,316,606 ('606), in response to applicant's remarks that rejection is prohibited under 35 U.S.C. 121 and should be withdrawn.

Claims 1-7,9,10 and 12 are currently pending in this application.

Claims 1-7,9,10 and 12 are allowed.

- 2. The following is an examiner's statement of reasons for allowance: The claimed crosslinked glycopolymers, containing a repeating unit, which is comprised of:
- (1) a saccharide consisting of glucopyranose and/or

(2) a bifunctional or polyfunctional aliphatic compound consisting of a dicarboxylic acid, a diol, a diamine and a diisocyanate, which is the underlying glycopolymers or copolymers having a repeating unit consist of a saccharide component and a bifunctional compound (second component) wherein bifunctional compound is a diamine or a dicarboxylic acid, is not taught or fairly suggested by the prior art of the record.

Art Unit: 1623

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-1235.

Devesh Khare, Ph.D.,J.D. Art Unit 1623 December 21,2004

JAMES O. WILSON

SOPERVISCELY OF ITEM EVALUATER TECHNOLOGY CENTER 1600